Our vision: individualize cancer medicine
IR Side Nav
Investor Contact Sylke Maas, Ph.D.
VP Investor Relations & Business Strategy
Send Email
+49 6131 9084-0
VP Investor Relations & Business Strategy
Send Email
+49 6131 9084-0
Media Contact Jasmina Alatovic
Director Global External Communications
Send Email
+49 6131 9084-0
Director Global External Communications
Send Email
+49 6131 9084-0
SEC Filings
Filing date | Description | Form | View |
---|---|---|---|
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K | View HTML | |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K | View HTML | |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K | View HTML | |
Form of prospectus reflecting facts events constituting substantive change from last form |
424B3 | View HTML | |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K | View HTML | |
Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3 |
424B5 | View HTML | |
EFFECT |
EFFECT | View HTML | |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K | View HTML | |
This filing is a pre-effective amendment to an F-1 filing |
F-1/A | View HTML | |
FWP |
FWP | View HTML |
Displaying 61 - 70 of 141 results
Data provided by Kaleidoscope.